On April 14, 2026 Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, reported the appointment of Prof Dr Wolfram Brugger as Chief Medical Officer. Prof Dr Brugger, who has been involved in more than 130 Phase I-III clinical oncology trials with numerous modalities across a wide variety of cancer types, including solid tumors, will strengthen Asgard’s leadership as it prepares to transition to a clinical-stage biotech.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cristiana Pires, Co-founder and Chief Executive Officer of Asgard Therapeutics, said: "Strengthening our leadership team with Wolfram, who is such a highly experienced clinical trials expert and practicing medical oncologist, is a privilege and we are excited to welcome him on board. Wolfram’s proven capabilities and track record will ensure that Asgard is perfectly positioned as we advance AT-108 towards the clinic."

Prof Dr Wolfram Brugger, incoming Chief Medical Officer of Asgard Therapeutics, said: "I’ve always been driven by bringing new modalities to patients, and I am excited to be developing a ‘personalized off-the-shelf’ immunotherapy which has great potential to help patients with a wide variety of cancers. Asgard’s in vivo cell reprogramming technology has transformative potential, and the pre-clinical proof-of-concept data, both published and upcoming data to be presented at key scientific conferences, is highly convincing. Having treated hundreds of cancer patients in clinical trials throughout my career, I look forward to utilizing my experience to shape Asgard’s clinical strategy, driving AT-108 through clinical development."

Wolfram joins Asgard from NASDAQ-listed Autolus Therapeutics where he led the global clinical development program of AUTO1 (AUCATZYL / obe-cel), an autologous CD19 CAR T therapy, in hematological and autoimmune indications. AUTO1 received FDA approval in 2024 for relapsed / refractory B-cell acute lymphoblastic leukemia (B-ALL) and conditional approval was granted by the EMA and MHRA in 2025. Prior to this he was at MorphoSys where he headed the global clinical development program for the monoclonal antibody tafasitamab across various blood cancer indications. Tafasitamab (in combination with lenalidomide) was granted accelerated approval by the FDA in relapsed/refractory DLBCL in 2020 and conditional approval by the EMA in the same indication in 2021. At AstraZeneca, he was global medical lead for Phase I / early Phase II trials for several oncology assets in numerous cancer types, including testing them in combination with checkpoint inhibitors.

Prior to moving into drug development, he was Chief & Medical Director in the Department of Hematology, Oncology, Immunology & Infectious Diseases at a Teaching Hospital of Freiburg University in Germany. He holds an MD and PhD from Albert-Ludwigs University Freiburg and Eberhard-Karls University Tübingen, Germany, with a specialist registration in Internal Medicine, Medical Oncology and Hematology.

Asgard is currently focused on advancing IND-enabling studies and CMC activities to support clinical development of AT-108. Key proof-of-concept data on AT-108 were published in 2024 in the high-impact, peer-reviewed journal Science.

(Press release, Asgard Therapeutics, APR 14, 2026, View Source [SID1234664348])

On April 14, 2026 Adcendo, a biotech company focused on the development of first-and best-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical need, reported the successful closing of an oversubscribed $75 million Series C financing round. Proceeds from the fundraise will be used to support Adcendo through multiple upcoming key clinical milestones from the Company’s first- and best-in-class ADC pipeline, including the ADCE-T02 (Tissue Factor ADC) Phase I Tiffany-01 Cohort expansion study in multiple high unmet need tumor indications, the ADCE-D01 (uPARAP) ADCElerate1 dose escalation and expansion study in soft tissue sarcoma and other cancers of mesenchymal origin, and the ADCE-B05 (undisclosed target) dose escalation study in squamous cell carcinomas.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The financing round was led by Jeito Capital, with participation from additional new investors Vida Ventures, BPI France, and EIFO (Export and Investment Fund of Denmark), as well as all existing investors, including TCGX, RA Capital Management, TPG, Orbimed, Venrock, Surveyor, Logos Capital, Novo Holdings, Pontifax Venture Capital, Dawn Biopharma, a platform controlled by KKR, HealthCap, Gilde Healthcare and Ysios Capital.

"This successful financing round, led by a distinguished group of life science investors, empowers us to continue advancing our pipeline of breakthrough ADCs for the treatment of underserved cancers," said Michael Pehl, Chief Executive Officer of Adcendo. "We are thrilled to see continued momentum of our first and best-in-class ADCs in clinic, and with the backing of this fundraising we will continue to progress ADCE-T02, ADCE-D01 and ADCE-B05 through upcoming data readouts."

Ksenija Pavletic, General Partner & Chief Commercial Officer at Jeito Capital, commented: "Adcendo stands out in the ADC field as having a noteworthy combination of bold innovation and strong clinical development strategy and execution. With a seasoned team of drug developers and biopharma leaders advancing their differentiated pipeline, we are excited to see the Company’s progress toward their mission of delivering next-generation cancer therapies to patients who need them most."

As part of the financing, Adcendo will add Ksenija Pavletic (Jeito Capital) and Rajul Jain (Vida Ventures) to its Board of Directors.

(Press release, ADCendo, APR 14, 2026, View Source [SID1234664347])

On April 14, 2026 Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, reported the signing of a Commercial Manufacturing Agreement for 64Cu-SAR-bisPSMA with Nucleus Radiopharma, an innovative contract development and manufacturing organisation (CDMO) in the radiopharmaceutical industry, dedicated to the development and manufacturing of targeted radiotherapies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Agreement relates to Nucleus RadioPharma’s state-of-the-art facility in Rochester, Minnesota, which is capable of manufacturing around 50,000 patient doses per year, and future production in Spring House, Pennsylvania. The Spring House facility is a 47,000 square foot site that is planned to open in 2028, enabling broad coverage across the northeast of the US with up to 600,000 doses of 64Cu-SAR-bisPSMA per year. Together, these two facilities in Minnesota and Pennsylvania will provide access to key commercial markets with manufacturing and distribution to all 50 states in the US and select international sites, including Europe.

The Commercial Manufacturing Agreement further builds on Clarity’s existing partnership with Nucleus RadioPharma with a Master Services Agreement and 67Cu-SAR-bisPSMA Clinical Supply Agreement in place from November 20241, covering the existing site in Rochester with additional facilities in Pennsylvania2 and future strategic sites to expand patient access.

This Agreement represents an important step in Clarity’s continued build out of its manufacturing capabilities ahead of 64Cu-SAR-bisPSMA’s anticipated commercial launch upon successful completion of Phase III registrational trials with this product, AMPLIFY3 and CLARIFY4, and subsequent US Food and Drug Administration (FDA) New Drug Application (NDA) approval.

Geoffrey Johnson, MD, PhD, Chief Scientific Officer of Nucleus RadioPharma, commented, "Nucleus RadioPharma is excited to produce a next-generation diagnostic imaging agent, 64Cu-SAR-bisPSMA, that data shows is capable of visualising tiny prostate cancer lesions that the current standard of care prostate specific membrane antigen (PSMA) positron emission tomography (PET) fails to detect. Earlier cancer detection and better cancer staging directly affects patient management and treatment outcomes and I firmly believe that seeing is saving. At Nucleus RadioPharma, we are proud to be driving demonstrable advances at the cutting edge of theranostics."

Stephen Hahn, MD, Chief Executive Officer of Nucleus RadioPharma, commented, "We are pleased to continue growing our partnership with Clarity through this new Commercial Manufacturing Agreement. At Nucleus RadioPharma, we share Clarity’s goal of improving treatment outcomes for patients with cancer and look forward to delivering novel products to people in need of better diagnostic and therapeutic options. 64Cu-SAR-bisPSMA is now quickly approaching its market launch, and with recently released data highlighting its detection benefits in comparison to standard of care PSMA PET, we could not be more excited about being part of the change in shaping the future of prostate cancer diagnostics."

Dr Alan Taylor, Executive Chairperson of Clarity Pharmaceuticals, commented, "Clarity is building a strong foundation with its supply and manufacturing strategy to support a large-scale commercial rollout of 64Cu-SAR-bisPSMA from day one, with capability to supply not only the entire existing PSMA PET market, but a larger pool of patients that could benefit from our optimised product, given the promising data we have seen in the clinic to date. With large-scale drug product manufacturing, reinforced by large-scale copper-64 production, we will be able to provide 64Cu-SAR-bisPSMA on demand through centralised manufacturing and distribution, broadly with sites servicing the entirety of the US and beyond, including sites close to areas of high demand. The half-life of copper-64 gives us the freedom to deliver a number of models in order to meet the future demand for our products.

"Together with Clarity’s existing copper-64 supply agreements with SpectronRx, Nusano and Theragenics, as well as a 64Cu-SAR-bisPSMA commercial manufacturing agreement with SpectronRx, the new Agreement with Nucleus RadioPharma further enhances Clarity’s broad network of high-volume production in distinct US geographies, building a tiered approach with regional distribution. The network is designed to support commercial-scale demand with secure, seamless and abundant supply and manufacturing.

"Nucleus RadioPharma is a trusted partner with extensive expertise in radiopharmaceuticals across not only the supply and manufacturing side, but also with a unique insight into the impact that radiopharmaceuticals can have on the healthcare system, treating clinicians and their patients. We look forward to continuing to work with their team as we continue to deliver on our promise of improving treatment outcomes for patients with cancer."

The Commercial Manufacturing Supply Agreement is effective as of 14 April 2026. Cancellation and extension provisions are aligned with industry standard rates.

(Press release, Clarity Pharmaceuticals, APR 14, 2026, View Source [SID1234664315])

On April 13, 2026 AstraZeneca reported the company has secured marketing approval from China’s National Medical Products Administration (NMPA) for Imjudo (tremelimumab). The CTLA-4 inhibitor is approved for use in combination with Imfinzi (durvalumab) and platinum-based chemotherapy as a first-line treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are negative for EGFR sensitive mutations and ALK alterations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Regulatory Approval & Clinical Basis
Component Detail
Regimen Imjudo (tremelimumab) + Imfinzi (durvalumab) + Platinum Chemotherapy
Indication 1L metastatic NSCLC (EGFR-/ALK-)
Basis for Approval Phase III POSEIDON clinical trial
Dosing Schedule Tremelimumab: 5 cycles; Durvalumab + Chemo: 4 cycles

POSEIDON Trial Key Results
Endpoint Combination Regimen Chemotherapy Alone Hazard Ratio (HR) p-value
Overall Survival (OS) Median 14.0 months; 2-year rate ~33% Median 11.7 months; 2-year rate 22% HR 0.77 (95% CI: 0.65–0.92) 0.00304
Progression-Free Survival (PFS) Significant improvement — HR 0.72 (95% CI: 0.60–0.86) 0.00031
Safety Consistent with known profiles of Imjudo and Imfinzi; no new safety signals identified

Drug Mechanism & Strategic Context
Mechanism of Action: Tremelimumab, a first-generation anti-CTLA-4 monoclonal antibody (originally from Pfizer), blocks the CTLA-4 checkpoint on T-cells, thereby enhancing their activation and anti-tumor immune response.
Differentiated IO Approach: This approval establishes AstraZeneca’s unique STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab) in China, differentiating it from other PD-(L)1-based combinations by adding a short course of CTLA-4 inhibition for a potent, yet time-limited, immune boost.
Addressing High Unmet Need: The approval provides a new, more effective standard of care for the large population of Chinese NSCLC patients without actionable EGFR or ALK drivers, who have historically relied on chemotherapy alone.
Market Impact
Competitive Edge: The significant 23% reduction in risk of death and improved long-term survival rates position the Imjudo/Imfinzi combo as a highly compelling option in the crowded first-line NSCLC market.
Franchise Expansion: This approval significantly broadens the commercial footprint of AstraZeneca’s immuno-oncology franchise in China, leveraging the established presence of Imfinzi.
Global Validation: The NMPA’s decision, based on the global POSEIDON data, reinforces the regimen’s efficacy and safety, supporting its adoption as a new global standard of care.

(Press release, AstraZeneca, APR 13, 2026, View Source [SID1234665020])

On April 13, 2026 Neomorph, Inc., a biotechnology company pioneering molecular glue degraders to address previously undruggable proteins, reported the closing of a $100 million Series B financing. The round was led by Deerfield Management with participation from new investors Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, Binney Street Capital of Dana-Farber Cancer Institute, and others.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This financing is a testament to the science, strategy, and team we have built at Neomorph, and it provides us with the capital to execute on our most important near-term priorities," said Phil Chamberlain, D.Phil., Co-Founder, President, and Chief Executive Officer of Neomorph. "We remain focused on executing the Phase 1/2 trial of NEO-811 to generate clinical data that will inform continued development, while advancing a broader pipeline of novel molecular glue degraders against targets that have historically been considered undruggable. We are delighted to welcome new partners and grateful for the continued support of our founding investor, Deerfield. We look forward to working together to deliver innovative medicines for patients with significant unmet need."

Proceeds from the financing will primarily support the advancement of the ongoing NEO-811 Phase 1/2 trial, a first-in-human, open-label monotherapy study evaluating the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity in patients with locally advanced or metastatic non-resectable clear cell renal cell carcinoma (ccRCC). The capital will also support advancement of Neomorph’s pipeline across multiple therapeutic areas, driven by its proprietary platform to unlock targets that have historically been unreachable with conventional drug discovery.

"We believe that Neomorph has built a differentiated platform with the scientific depth to systematically access a vast new target space, as well as a team with the expertise to translate key findings into compelling drug candidates," said Cam Wheeler, Ph.D., Partner at Deerfield Management and Chair of Neomorph’s board of directors. "Additionally, the confidence of leading global pharmaceutical companies, including Novo Nordisk, Biogen, and AbbVie, who have partnered with Neomorph across cardiometabolic disease, rare disease, neurology, oncology, and immunology, speaks to the versatility of this platform and provides multiple potential paths to validation. We are proud to continue supporting Neomorph as the company advances its molecular glue technology through clinical trials and works to redefine the universe of therapeutic targets available to physicians and patients."

About NEO-811
NEO-811 is an investigational molecular glue degrader designed to induce targeted degradation of a protein called ARNT, also known as HIF-1β, and fully block a central signaling pathway implicated in ccRCC. By leveraging a differentiated degradation mechanism, NEO-811 has the potential to address underlying tumor biology that remains inadequately treated with current standards of care. NEO-811 is currently being evaluated as a monotherapy in a first-in-human Phase 1/2 clinical trial in patients with locally advanced or metastatic non-resectable ccRCC.

(Press release, Neomorph, APR 13, 2026, View Source [SID1234664345])